ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

National Health Organizations Warn of Risks in Indoor Tanning

April 29, 2011

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

AZT Trial Unblended, Controls Get Drugs; Gallo, Essex Win Lasker With Montagnier

September 26, 1986

HHS Reports Some Gains In Reducing Health Disparities

February 8, 2002

NIH Director Collins Publishes Third Book About Faith In God

March 5, 2010

DD Should Transfer Part of Breast Cancer $$ To NIH r Peer Distribution, Broder Says

December 4, 1992